NCCN is holding the NCCN Oncology Research Best Practices Conference(TM), an interactive forum to discuss the regulatory and operational aspects of research and help identify areas in the clinical trial process where improvements can be made. Scheduled for October 26 - 27 in Bethesda, MD, the conference will include lectures, interactive workshops, and panel discussions on topics that challenge the conduct of oncology research as well as topics related to ethical considerations.
FORT WASHINGTON, Pa., Sept. 14 /PRNewswire-USNewswire/ -- Significant strides in the prevention, detection, and treatment of cancer have been made possible through clinical trials, however regulatory and ethical issues can pose challenges to clinical investigators. The National Comprehensive Cancer Network (NCCN), an alliance of 21 of the world's leading cancer centers, is drawing on its collective expertise and holding the NCCN Oncology Research Best Practices Conference(TM) to review and discuss regulatory and operational aspects of research and help identify areas in the clinical trial process where improvements can be made.
The two-day conference being held October 26 - 27 in Bethesda, MD, will include lectures, interactive workshops, and panel discussions with audience participation on topics that challenge the conduct of oncology research as well as topics related to ethical considerations and maintaining and improving regulatory compliance. Attendees will learn about innovative practices and organizational structures that work and new ideas and perspectives that will lead to increased productivity and quality.
The conference is designed to be interactive and meet the needs of a multidisciplinary audience including oncology researchers, research nurses, Institutional Review Board (IRB) professionals, research administrators, academics, ethicists, government regulators, and industry sponsors on best practices in oncology research.
NCCN recognizes the importance of investing in clinical trials, which can result in changes in the standard of care and improved patient outcomes. Through the NCCN Oncology Research Program (ORP), more than $20 million of funding has been obtained to support investigator-initiated trials at NCCN Member Institutions to explore new avenues of clinical investigation and answer important scientific questions. The NCCN ORP recently launched a new platform, the Drug Development Research Grant Model that provides a mechanism for research on drugs in early stages of development.
Complete program details and online registration for the NCCN Oncology Research Best Practices Conference(TM) are available at NCCN.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center / Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
For more information on NCCN, please visit NCCN.org.
|SOURCE National Comprehensive Cancer Network|
Copyright©2009 PR Newswire.
All rights reserved